Latest News & Features

Reset all filters
Article Type
Channels & Sectors
Geography
Company

Refine Search
Biotechnology
The English High Court has allowed Japan-based drug maker Fujifilm Kyowa Kirin Biologics to amend some of its arguments in a patent dispute surrounding AbbVie’s arthritis drug Humira.   8 March 2016
Americas
Pharmaceutical company Teva has bought Mexico-based Representaciones e Investigaciones Médicas, in a deal totalling $2.3 billion.   8 March 2016
Americas
The International Trade Commission has invalidated two patents owned by Jawbone because they cover “ineligible subject matter”, dealing a blow to the wearable fitness company in its legal battle with rival Fitbit.   7 March 2016
Americas
A US court has brought to a close a patent lawsuit that cancer care company Helsinn Healthcare filed against Teva after determining that Helsinn did not trigger the on-sale bar provision when marketing its anti-cancer drug Aloxi (palonosetron).   4 March 2016
Africa
Despite several UK court decisions centring on second medical use patents, there are no foolproof ways for generic manufacturers to avoid infringement, as Deborah Hart of Kilburn & Strode explains.   3 March 2016
Americas
Amgen and Sandoz are set to go head to head in another patent case, this time centring on Amgen’s arthritis treatment drug Enbrel.   3 March 2016
Asia
Médecins Sans Frontières has urged the Indian Patent Office to reject a Gilead Sciences patent application covering Sovaldi.   2 March 2016
Americas
Law firm Mintz, Levin, Cohn, Ferris, Glovsky and Popeo has expanded its intellectual property capabilities by hiring William Kezer as a member.   2 March 2016
Americas
The Patent Trial and Appeal Board’s process of allowing the same three judges to decide whether to institute an inter partes review and on the validity of the patent in question creates legal biases, Ethicon Endo-Surgery has argued.   1 March 2016
Big Pharma
The European Commission is considering whether ‘export waivers’ should be introduced in order to partly relax the rules on supplementary protection certificates. Gareth Morgan of Olswang explains more.   1 March 2016